Nexstim logo

Increase of Nexstim Plc’s share capital with subscriptions based on stock options 2013A, 16 January 2017

16 January 2017

Nexstim Plc (NXTMH: HEX, NXTMS: STO) is a medical technology company aiming to improve rehabilitation for stroke patients with the use of non-invasive brain stimulation. The company announces the subscription of 256,035 new shares in Nexstim Plc based on stock options 2013A. The corresponding increase in the company’s share capital, i.e. EUR 2560,35 to be credited to the company’s invested unrestricted equity, will be registered in the Trade Register on or around 19 January 2017. Trading in the new shares registered at this time will commence on the Nasdaq First North Finland and Nasdaq First North Sweden on or around 20 January 2017. The right to dividends and other rights conferred by shares will come into effect when the increase in share capital has been registered in the Trade Register.Nexstim Plc holds a total of 772,268 stock options under the stock option plans 2016 and 2013A. The remaining outstanding stock options 2013A provide entitlement to subscribe for a maximum of 309,792 shares for EUR 0.01 per share. The share subscription period for stock option 2016 ends on 15 December 2025 and for stock option 2013A on 31 December 2020.

Nexstim Plc’s share capital will be EUR 80,000 after the increase.

 

NEXSTIM PLC

Martin Jamieson, CEO

 

Further information is available on the website www.nexstim.com or by contacting:

 

Nexstim                                                                                                                                

Martin Jamieson, CEO                                                                                     +447715163942

                                                                                                martin.jamieson@nexstim.com

 

UB Securities Oy (Certified Adviser)                                                          +358 (0)9 2538 0246

 

About Nexstim Plc

Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology as a diagnostic tool for brain surgery with its Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE-marked system based on the navigated transcranial magnetic stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the company has developed a device called Navigated Brain Therapy (NBT®) for use in the rehabilitation of stroke patients. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Back to Press Releases

Sorry, there are no fact sheets available. Please check back soon.

Follow us

linkedin

Twitter
YouTube